Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026GlobeNewsWire · 3 days ago
Financial Analysis: Elutia (NASDAQ:ELUT) & QuidelOrtho (NASDAQ:QDEL)Defense World · Oct 18, 2026
Analyzing Elutia (NASDAQ:ELUT) and Edwards Lifesciences (NYSE:EW)Defense World · Oct 12, 2026
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029GlobeNewsWire · Oct 1, 2026
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15thGlobeNewsWire · Sep 10, 2026
Jushi (OTCMKTS:JUSHF) vs. Elutia (NASDAQ:ELUT) Head-To-Head SurveyDefense World · Sep 9, 2026Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.15 | -$0.17 | Miss |
| May 14, 2026 | -$0.15 | -$0.17 | Miss |
| Mar 11, 2026 | -$0.14 | -$0.14 | Beat |
| Nov 6, 2025 | -$0.16 | -$0.01 | Beat |
| Aug 14, 2025 | -$0.17 | -$0.26 | Miss |
| May 8, 2025 | -$0.20 | -$0.21 | Miss |